Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 263

1.

Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion.

Bunney WE Jr, Azarnoff DL, Brown BW Jr, Cancro R, Gibbons RD, Gillin JC, Hullett S, Killam KF, Kupfer DJ, Krystal JH, Stolley PD, French GS, Pope AM.

Arch Gen Psychiatry. 1999 Apr;56(4):349-52. No abstract available.

PMID:
10197830
2.

The report by the Institute of Medicine and postmarketing surveillance.

Klein DF.

Arch Gen Psychiatry. 1999 Apr;56(4):353-4. No abstract available.

PMID:
10197831
3.

Long-term use of sedative and hypnotic medication.

Dunner DL.

Arch Gen Psychiatry. 1999 Apr;56(4):355. No abstract available.

PMID:
10197832
4.

The risks of pharmacological therapy for insomnia (part 1): update for the clinical nurse specialist.

O'Malley P.

Clin Nurse Spec. 2007 Jul-Aug;21(4):188-90. Review. No abstract available.

PMID:
17622806
5.

The pit (of sleeplessness) and the pendulum (of regulation).

Bliwise DL.

Sleep Med. 2010 Jan;11(1):7-8. doi: 10.1016/j.sleep.2009.08.002. Epub 2009 Nov 28. No abstract available.

PMID:
19945339
6.

Zolpidem: distinct from triazolam?

Lobo BL, Greene WL.

Ann Pharmacother. 1997 May;31(5):625-32. Review.

PMID:
9161660
7.

Insomnia medication: do published studies reflect the complete picture of efficacy and safety?

Mattila T, Stoyanova V, Elferink A, Gispen-de Wied C, de Boer A, Wohlfarth T.

Eur Neuropsychopharmacol. 2011 Jul;21(7):500-7. doi: 10.1016/j.euroneuro.2010.10.005. Epub 2010 Nov 16.

PMID:
21084176
8.

Insomnia market.

Gershell L.

Nat Rev Drug Discov. 2006 Jan;5(1):15-6. No abstract available. Erratum in: Nat Rev Drug Discov. 2006 Jun;5(6):469.

PMID:
16485342
9.

[Halcion (triazolam) in the treatment of insomnia].

Muzychenko AP, Prokudin VN, Bogdan AN.

Ter Arkh. 1997;69(1):65-8. Russian.

PMID:
9163057
10.

Lost in transmission--FDA drug information that never reaches clinicians.

Schwartz LM, Woloshin S.

N Engl J Med. 2009 Oct 29;361(18):1717-20. doi: 10.1056/NEJMp0907708. Epub 2009 Oct 21. No abstract available.

11.

How should adverse events be reported in US clinical trials?: ethical considerations.

Shamoo AE, Katzel LI.

Clin Pharmacol Ther. 2008 Aug;84(2):275-8. doi: 10.1038/clpt.2008.14. Epub 2008 Feb 27.

PMID:
18305454
12.

Sleeping pills, insomnia and medical practice.

Solomon F, White CC, Parron DL, Mendelson WB.

N Engl J Med. 1979 Apr 5;300(14):803-8. No abstract available.

PMID:
34097
13.

Insomnia and the new benzodiazepines.

Wincor MZ.

Clin Pharm. 1982 Sep-Oct;1(5):425-32. Review. No abstract available.

PMID:
6135527
14.

Comment: long-term triazolam use.

[No authors listed]

DICP. 1989 Oct;23(10):814-5. No abstract available.

PMID:
2815861
15.

Protecting the health of the public--Institute of Medicine recommendations on drug safety.

Psaty BM, Burke SP.

N Engl J Med. 2006 Oct 26;355(17):1753-5. Epub 2006 Oct 9. No abstract available.

16.

Update on hypnotics for insomnia in clinical practice: I. Hypnotics.

DiBella GA.

Mt Sinai J Med. 1986 Feb;53(2):82-9. No abstract available. Erratum in: Mt Sinai J Med. 1986 Sep;53(7):577.

PMID:
3486358
17.

Who should sponsor sleep disorders pharmaceutical trials?

Kripke DF.

J Clin Sleep Med. 2007 Dec 15;3(7):671-3. No abstract available.

18.

Hypnotics: rebound insomnia and residual sequelae.

Nicholson AN.

Br J Clin Pharmacol. 1980 Mar;9(3):223-5. No abstract available.

19.

Institute of Medicine, Congress seek solutions to FDA's safety woes through reform, funding.

Finkelstein JB.

J Natl Cancer Inst. 2007 Jan 17;99(2):104-7. No abstract available.

20.

U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.

Goldman SA.

Food Drug Law J. 2007;62(3):513-28. No abstract available.

PMID:
17915393
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk